Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06952803 |
Title | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (EvoPAR-PR02) |
Acronym | EvoPAR-PR02 |
Recruitment | Not yet recruiting |
Gender | male |
Phase | Phase III |
Variant Requirements | No |
Sponsors | AstraZeneca |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA | TUR | SWE | POL | ITA | HUN | FRA | FIN | ESP | DEU | CAN | BRA | BEL | AUT | AUS |